Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

ClinicalTrials.gov ID: NCT02171156

Public ClinicalTrials.gov record NCT02171156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis

Study identification

NCT ID
NCT02171156
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • nintedanib Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
May 7, 2017

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
1199.177.1003 Boehringer Ingelheim Investigational Site Winter Park Florida
1199.177.1012 Boehringer Ingelheim Investigational Site Skokie Illinois
1199.177.1014 Boehringer Ingelheim Investigational Site Muncie Indiana
1199.177.1002 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
1199.177.1011 Boehringer Ingelheim Investigational Site Charleston South Carolina
1199.177.1022 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1199.177.1067 Boehringer Ingelheim Investigational Site Houston Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02171156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2017 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02171156 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →